Although the widespread application of HER2-targeted therapies such as trastuzumab and pertuzumab has significantly prolonged survival, the prognosis for patients with pulmonary metastatic disease remains unsatisfactory (14). The gene discussed is ERBB2; the disease is metastatic neoplasm.